Potential roles of α-amylase in alzheimer’s disease: Biomarker and drug target

Research output: Contribution to journalReview ArticleResearchpeer-review

4 Citations (Scopus)


Alzheimer’s disease (AD), the most common form of dementia, is pathologically characterized by the deposition of amyloid-β plaques and the formation of neurofibrillary tangles. In a neurodegenerative brain, glucose metabolism is also impaired and considered as one of the key features in AD patients. The impairment causes a reduction in glucose transporters and the uptake of glucose as well as alterations in the specific activity of glycolytic enzymes. Recently, it has been reported that α-amylase, a polysaccharide-degrading enzyme, is present in the human brain. The enzyme is known to be associated with various diseases such as type 2 diabetes mellitus and hyperamylasaemia. With this information at hand, we hypothesize that α-amylase could have a vital role in the demented brains of AD patients. This review aims to shed insight into the possible link between the expression levels of α-amylase and AD. Lastly, we also cover the diverse role of amylase inhibitors and how they could serve as a therapeutic agent to manage or stop AD progression.

Original languageEnglish
Pages (from-to)1554-1563
Number of pages10
JournalCurrent Neuropharmacology
Issue number8
Publication statusPublished - 2022


  • alpha-amylase
  • Alzheimer’s disease
  • amyloid-beta
  • biomarker
  • drug repurposing
  • drug target
  • enzyme inhibitor
  • neurological disorders

Cite this